pteridines has been researched along with Experimental Neoplasms in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anaplastic thyroid cancer (ATC) is among the most lethal malignancies." | 1.48 | PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. ( De Martino, D; Di Cristofano, A; Orlacchio, A; Ranieri, M; Yilmaz, E; Zhao, K, 2018) |
| "Human esophageal squamous cell carcinoma (ESCC) cell lines KYSE 70 and KYSE 150 were used to evaluate the synergistic effect of volasertib and irradiation in vitro using cell viability assay, colony formation assay, cell cycle phase analysis, and western blot, and in vivo using ectopic tumor models." | 1.43 | Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition. ( Chen, JL; Chen, JP; Cheng, JC; Huang, YS; Jaw, FS; Kuo, SH; Shieh, MJ; Tsai, MH; Tsai, YC, 2016) |
| "SD-208 also blocked prostate cancer cell survival and invasion, and arrested cells in the G2/M phase of the cell cycle." | 1.42 | SD-208, a novel protein kinase D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest. ( Carder, EJ; Deng, F; Farber, E; Salamoun, JM; Tandon, M; Tang, H; Wang, QJ; Wipf, P; Xu, S, 2015) |
| "Volasertib (BI 6727) is a potent inhibitor of Polo-like kinase 1 (Plk1), that is overexpressed in several childhood cancers and cell lines." | 1.40 | Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. ( Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, R; Maris, JM; Reynolds, CP; Smith, MA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, NY | 1 |
| Xu, Y | 3 |
| Xiao, KJ | 1 |
| Zuo, WQ | 1 |
| Zhu, YX | 1 |
| Hu, R | 1 |
| Wang, WL | 1 |
| Shi, YJ | 1 |
| Yu, LT | 1 |
| Liu, ZH | 1 |
| Viswanath, P | 1 |
| Peng, S | 1 |
| Singh, R | 1 |
| Kingsley, C | 1 |
| Balter, PA | 1 |
| Johnson, FM | 1 |
| De Martino, D | 1 |
| Yilmaz, E | 1 |
| Orlacchio, A | 1 |
| Ranieri, M | 1 |
| Zhao, K | 1 |
| Di Cristofano, A | 1 |
| Gorlick, R | 1 |
| Kolb, EA | 1 |
| Keir, ST | 1 |
| Maris, JM | 1 |
| Reynolds, CP | 1 |
| Kang, MH | 1 |
| Carol, H | 1 |
| Lock, R | 1 |
| Billups, CA | 1 |
| Kurmasheva, RT | 1 |
| Houghton, PJ | 1 |
| Smith, MA | 1 |
| Li, Z | 1 |
| Li, J | 1 |
| Bi, P | 1 |
| Lu, Y | 1 |
| Burcham, G | 1 |
| Elzey, BD | 1 |
| Ratliff, T | 1 |
| Konieczny, SF | 1 |
| Ahmad, N | 1 |
| Kuang, S | 1 |
| Liu, X | 1 |
| Tandon, M | 1 |
| Salamoun, JM | 1 |
| Carder, EJ | 1 |
| Farber, E | 1 |
| Xu, S | 1 |
| Deng, F | 1 |
| Tang, H | 1 |
| Wipf, P | 1 |
| Wang, QJ | 1 |
| Chen, JL | 1 |
| Chen, JP | 1 |
| Huang, YS | 1 |
| Tsai, YC | 1 |
| Tsai, MH | 1 |
| Jaw, FS | 1 |
| Cheng, JC | 1 |
| Kuo, SH | 1 |
| Shieh, MJ | 1 |
| Hao, Y | 1 |
| Wang, X | 1 |
| Zhang, T | 1 |
| Sun, D | 1 |
| Tong, Y | 1 |
| Chen, H | 1 |
| Tong, L | 1 |
| Zhu, L | 1 |
| Zhao, Z | 1 |
| Chen, Z | 1 |
| Ding, J | 1 |
| Xie, H | 1 |
| Li, H | 1 |
| Katoh, S | 1 |
| Sueoka, T | 1 |
| Hirayama, K | 1 |
| Masuda, I | 1 |
| Nakanishi, N | 1 |
| Yamada, S | 1 |
| Kokolis, N | 1 |
| Ziegler, I | 1 |
| Pomerantz, SH | 1 |
11 other studies available for pteridines and Experimental Neoplasms
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Cell Survival; D | 2020 |
A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice.
Topics: Animals; Antineoplastic Agents; Lung Neoplasms; Male; Mice, Inbred Strains; Mice, Transgenic; Neopla | 2018 |
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Prote | 2018 |
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitu | 2014 |
Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Transformati | 2014 |
SD-208, a novel protein kinase D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest.
Topics: Animals; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints | 2015 |
Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Ce | 2016 |
Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Dru | 2016 |
[Phenylalanine hydroxylating activity in Tawa sarcoma].
Topics: Animals; Biopterins; Hydroxylation; Liver Neoplasms; Neoplasms, Experimental; Phenylalanine Hydroxyl | 1981 |
On the levels of phenylalanine, tyrosine and tetrahydrobiopterin in the blood of tumor-bearing organisms.
Topics: Animals; Biopterins; Blood Proteins; Female; Humans; Hydroxylation; Male; Neoplasms; Neoplasms, Expe | 1977 |
Tyrosine hydroxylation catalyzed by mammalian tyrosinase: an improved method of assay.
Topics: Animals; Cricetinae; Dihydroxyphenylalanine; In Vitro Techniques; Kinetics; Melanoma; Neoplasms, Exp | 1964 |